全文获取类型
收费全文 | 1432篇 |
免费 | 76篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 31篇 |
妇产科学 | 17篇 |
基础医学 | 130篇 |
口腔科学 | 23篇 |
临床医学 | 130篇 |
内科学 | 526篇 |
皮肤病学 | 9篇 |
神经病学 | 90篇 |
特种医学 | 18篇 |
外科学 | 231篇 |
综合类 | 7篇 |
预防医学 | 88篇 |
眼科学 | 6篇 |
药学 | 83篇 |
中国医学 | 2篇 |
肿瘤学 | 111篇 |
出版年
2023年 | 11篇 |
2022年 | 23篇 |
2021年 | 36篇 |
2020年 | 22篇 |
2019年 | 15篇 |
2018年 | 27篇 |
2017年 | 18篇 |
2016年 | 27篇 |
2015年 | 23篇 |
2014年 | 43篇 |
2013年 | 54篇 |
2012年 | 60篇 |
2011年 | 97篇 |
2010年 | 48篇 |
2009年 | 49篇 |
2008年 | 71篇 |
2007年 | 102篇 |
2006年 | 75篇 |
2005年 | 73篇 |
2004年 | 77篇 |
2003年 | 65篇 |
2002年 | 59篇 |
2001年 | 41篇 |
2000年 | 32篇 |
1999年 | 20篇 |
1998年 | 12篇 |
1997年 | 5篇 |
1996年 | 6篇 |
1995年 | 11篇 |
1994年 | 9篇 |
1993年 | 12篇 |
1992年 | 24篇 |
1991年 | 15篇 |
1990年 | 26篇 |
1989年 | 23篇 |
1988年 | 24篇 |
1987年 | 19篇 |
1986年 | 21篇 |
1985年 | 10篇 |
1984年 | 8篇 |
1983年 | 20篇 |
1982年 | 5篇 |
1980年 | 6篇 |
1979年 | 9篇 |
1978年 | 19篇 |
1977年 | 15篇 |
1975年 | 6篇 |
1970年 | 4篇 |
1968年 | 5篇 |
1966年 | 5篇 |
排序方式: 共有1514条查询结果,搜索用时 15 毫秒
991.
We describe a patient in whom a chronic expanding hematoma was pathologically confirmed by examination of the resected specimen. It developed gradually in the left lateral thigh, which had been bruised 8 months before, but had produced no mass-related symptoms initially. Computed tomography (CT) showed the mass to be homogeneous with capsule formation, whereas ultrasonography showed it to resemble a multilocular cyst. The lesion was treated by complete excision of a perifascial mass. Grossly, a well-circumscribed, fusiform mass with a soft cystic center and a fibrous pseudocapsule was observed. Histologically, the mass was composed of necrotic debris, fibrin and blood clots. This was surrounded by a rim of hyalinized fibrous tissue with a chronic inflammatory infiltrate and granulation tissue with sprouting new capillaries. CT was unable to discriminate the chronic expanding hematoma from other soft tissue masses, ultrasonography being needed to reveal its characteristics in this case. 相似文献
992.
993.
Shigenori Kadowaki Yasushi Yatabe Sohei Nitta Yuichi Ito Kei Muro 《Case reports in oncology》2014,7(1):210-216
Here, we report a patient with gastric adenosquamous carcinoma (ASC) with human epidermal growth factor receptor-2 (HER2) overexpression who was successfully treated with trastuzumab-based chemotherapy. The patient was a 66-year-old man preoperatively diagnosed with gastric adenocarcinoma with no evidence of distant metastases. On histopathological examination, the curatively resected tumor was identified as ASC with mixed adenocarcinoma and squamous cell carcinoma components. Multiple liver metastases developed 2.5 months after surgery. Because immunohistochemical staining for HER2 was strong in both components, combination chemotherapy with capecitabine, cisplatin, and trastuzumab was initiated. A partial response was confirmed after 6 treatment cycles and PET and CT scans performed after 13 cycles revealed disease resolution with no uptake in the metastatic lesions. No evidence of disease progression has been observed 16 months after initial chemotherapy. This report suggests the potential utility of trastuzumab-based chemotherapy for HER2-positive gastric ASC.Key Words: Adenosquamous carcinoma, Stomach, Human epidermal growth factor receptor-2, Trastuzumab 相似文献
994.
Yukiya Narita Hiroya Taniguchi Azusa Komori Sohei Nitta Kazuhisa Yamaguchi Chihiro Kondo Motoo Nomura Shigenori Kadowaki Daisuke Takahari Takashi Ura Masashi Andoh Kei Muro 《Cancer chemotherapy and pharmacology》2014,73(2):409-416
Purpose
The prognostic and predictive values of carbohydrate antigen 19-9 (CA19-9) levels in metastatic colorectal cancer (mCRC) remain unclear. We reviewed all mCRC patients at a single institution to evaluate the relationship between CA19-9 levels and survival.Methods
Two hundred and fifty-two patients underwent first-line chemotherapy using oxaliplatin-based regimens between April 2005 and December 2009. The relationship between baseline CA19-9 levels and survival was analyzed. Moreover, we evaluated the relationship between baseline CA19-9 levels and clinicopathological factors.Results
One hundred and fifty patients had elevated baseline CA19-9 levels (elevated group), and 79 patients had normal baseline CA19-9 (normal group) levels. Both KRAS and BRAF mutation rates were higher in the elevated group than in the normal group. Elevated CA19-9 level was a poor prognostic factor compared with normal CA19-9 levels (P = 0.0021). In the elevated group, the median survival time with bevacizumab was significantly longer with bevacizumab than without it (median OS, 27.8 vs. 15.3 months, P = 0.0019). However, the median survival time was not different with or without bevacizumab in the normal group (median OS, 36.5 vs. 38.0 months, P = 0.9515).Conclusion
Our results suggest that baseline CA19-9 level is an independent prognostic factor in mCRC patients, and it correlated with the KRAS/BRAF mutation status. Bevacizumab exhibits clinical activity only for high CA19-9 levels in mCRC. 相似文献995.
Takayuki Takimoto Takashi Kijima Yasushi Otani Shinpei Nonen Yoshinobu Namba Masahide Mori Soichiro Yokota Seigo Minami Kiyoshi Komuta Junji Uchida Fumio Imamura Mitsugi Furukawa Naotoshi Tsuruta Yasushi Fujio Junichi Azuma Isao Tachibana Atsushi Kumanogoh 《Clinical lung cancer》2013,14(5):502-507
IntroductionGefitinib induces severe hepatotoxicity in approximately a quarter of Japanese patients with epidermal growth factor receptor (EGFR) mutation–positive non–small-cell lung cancer (NSCLC). Gefitinib is metabolized by cytochrome P450 (CYP) enzymes—including CYP3A4/5, CYP1A1, and CYP2D6—in the liver. We hypothesized that polymorphisms of the CYP2D6 gene may account for gefitinib-induced hepatotoxicity.Patients and MethodsPolymorphisms of the CYP2D6 gene were analyzed in 55 patients with NSCLC who experienced grade ≥ 2 transaminase elevation from gefitinib. The distribution of the CYP2D6 genotype was compared with that of the healthy Japanese population. The correlations between the nonfunctional allele *5 or the reduced-function allele *10 and hepatotoxicity-related clinical factors were also examined.ResultsThe distribution of the CYP2D6 genotype in the study participants was not different from that of the general Japanese population, reported previously. Existence of allele *5 or *10 did not correlate with clinical factors such as onset of hepatotoxicity within 2 months, grade ≥ 3 serum transaminase elevation, and tolerability to dose reduction or rechallenge of gefitinib. However, in 7 patients taking CYP3A4-inhibitory drugs, rechallenge of gefitinib again caused hepatotoxicity in 4 patients with allele *5 or *10 but not in 3 patients with normal alleles (P = .029). Moreover, switching to erlotinib did not cause hepatotoxicity in any of 17 patients with allele *5 or *10 but did in 3 of 8 patients without these alleles (P = .024).ConclusionReduced function of CYP2D6 may partly account for gefitinib-induced hepatotoxicity when CYP3A4 is inhibited. Erlotinib could be safely used in patients with decreased CYP2D6 activity even after they experienced gefitinib-induced hepatotoxicity. 相似文献
996.
Mark A. Espeland PhD Richard E. Pratley MD Julio Rosenstock MD Takashi Kadowaki MD Yutaka Seino MD Bernard Zinman MD Nikolaus Marx MD Darren K. McGuire MD Knut Robert Andersen BSc Michaela Mattheus MSc Annett Keller PhD Maria Weber MD Odd Erik Johansen MD 《Diabetes, obesity & metabolism》2021,23(2):569-580
997.
998.
Shinpei Matsuda Ichiro Kawachi Ryousuke Fujita Hisato Yoshida Hisashi Oki Yasuo Kokubo Akihiko Matsumine Hitoshi Yoshimura 《Medicine》2022,101(46)
The coronavirus disease 2019 (COVID-19) pandemic affected the physical and mental health, socioeconomic status, and community behavior of people worldwide. The aim of this retrospective cohort study was to analyze the impact of the COVID-19 pandemic on the oral health and nutritional status of Japanese older adults based on the results of preoperative assessment in patients who underwent total hip or knee arthroplasty under general anesthesia. This study included older adults (≧65 years) who underwent total hip or knee arthroplasty in whom orthopantomography was performed for preoperative oral health assessment, during January 2019 to December 2021. Gender, age, number of family members living together, number of teeth, body mass index, and serum total protein and serum albumin levels were collected for analysis of this study. A total of 201 patients aged 65 to 89 years participated in the study. While the COVID-19 pandemic has had no impact on the oral health status, there has been a drop in serum albumin level from the results of multivariable-adjusted regression analysis considering age, gender, number of family members, and time. The COVID-19 pandemic has affected the serum albumin level of Japanese orthopedic patients aged 65 years or older. 相似文献
999.
Namuun Ganbaatar Aya Kadota Takashi Hisamatsu Shin-Ichi Araki Shinji Kume Akira Fujiyoshi Sayaka Kadowaki Sayuki Torii Keiko Kondo Hiroyoshi Segawa Ebtehal Salman Itsuko Miyazawa Takashi Yamamoto Yoshihisa Nakagawa Hiroshi Maegawa Katsuyuki Miura Hirotsugu Ueshima 《Journal of atherosclerosis and thrombosis》2022,29(9):1359
Aims: The roles of urinary albumin, eGFRcystatin (eGFRcys), and eGFRcreatinine (eGFRcre) in the progression of coronary artery calcification (CAC) remain unclear. Therefore, the present study investigated the relationship between kidney function and CAC progression. Methods: A total of 760 Japanese men aged 40-79 years were enrolled in this population-based study. Kidney function was measured using eGFRcre, eGFRcys, and the urine albumin-to-creatinine ratio. CAC scores were calculated using the Agatston method. CAC progression was defined as an annual increase of >10 Agatston units (AU) among men with 0<CAC<100 AU at baseline, that of >10% among those with CAC ≥ 100 AU, and any progression for those with CAC=0 at baseline. The relative risk (RR) of CAC progression based on kidney function was assessed using a robust Poisson regression model. Results: The mean follow-up period was 4.9 years. CAC progression was detected in 45.8% of participants. Positive associations between CAC progression and albuminuria (>30mg/g) (RR: 1.29; 1.09 to 1.53;p=0.004) and low eGFRcys (<60ml/min/1.73m2) (RR: 1.27; 1.05 to 1.53;p=0.012) remained significant after adjustments for age, the follow-up time, and computerized tomography type. Following further adjustments for hypertension, diabetes mellitus, dyslipidemia, C-reactive protein, and lifestyle factors, CAC progression was associated with albuminuria (RR: 1.20; 1.01 to 1.43;p=0.04) and low eGFRcys (RR: 1.19; 0.99 to 1.43;p=0.066), but not with eGFRcre. Conclusion: CAC progression was associated with albuminuria; however, its relationship with eGFRcys was weakened by adjustments for risk factors. 相似文献
1000.
Koichi Sugihara Risa Wakiya Hiromi Shimada Tomohiro Kameda Shusaku Nakashima Mikiya Kato Taichi Miyagi Mao Mizusaki Rina Mino Yumi Nomura Masayuki Inoo Norimitsu Kadowaki Hiroaki Dobashi 《Internal medicine (Tokyo, Japan)》2022,61(13):1953
Objective To investigate the serum total antibody (immunoglobulin M and immunoglobulin G) titre against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain following BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination in Japanese rheumatic disease patients undergoing immunosuppressive therapy. Methods The serum antibody titre against SARS-CoV-2 spike protein was analysed in 123 outpatients with rheumatic diseases at Kagawa University Hospital and 43 healthy volunteers who had received 2 doses of the BNT162b2 mRNA vaccine with at least 14 days elapsing since the second dose. Results The antibody titre in rheumatic disease patients was significantly lower than that in healthy subjects (p<0.0001). The antibody titres of the 41 patients who received biologics or Janus kinase inhibitors and the 47 patients who received conventional immunosuppressive agents were significantly lower than those of the 35 patients who did not receive immunosuppressive agents (p<0.0001 and p<0.0001, respectively). In addition, the mean antibody titre of the 43 patients on methotrexate was significantly lower than that of the 80 patients not on methotrexate (p=0.0017). Conclusion Immunogenicity to the BNT162b2 mRNA COVID-19 vaccine in rheumatic disease patients was found to be reduced under immunosuppressive treatment. In particular, methotrexate seems to be associated with a decreased antibody response. 相似文献